HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $95
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $75 to $95.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $75 to $95.